U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Hf.2O
Molecular Weight 210.49
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HAFNIUM OXIDE

SMILES

[O--].[O--].[Hf+4]

InChI

InChIKey=WIHZLLGSGQNAGK-UHFFFAOYSA-N
InChI=1S/Hf.2O/q+4;2*-2

HIDE SMILES / InChI

Molecular Formula Hf
Molecular Weight 178.49
Charge 4
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
MOL RATIO 2 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Hafnium oxide is a radio enhancer; its nanoparticles (NBTXR3) were designed for high dose energy deposition within cancer cells when exposed to ionizing radiation. When activated by radiotherapy (RT), NBTXR3 allows for a higher energy deposit than RT alone, yielding an increased tumoral cell death. Nanocrystals of hafnium oxide are under investigation in phase II/III in patients with locally advanced soft tissue sarcoma (STS) of the extremity and trunk wall. In addition, NBTXR3, nanoparticles are being studied in phase I/II in patients with head and neck cancer; liver cancer; prostate cancer and rectal cancer.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
One intratumor implantation by injection of NBTXR3 (Hafnium oxide nanocrystals) + Radiotherapy
Route of Administration: Other
Substance Class Chemical
Record UNII
3C4Z4KG52T
Record Status Validated (UNII)
Record Version